1,862 results found
    1. Cancer Biology
    2. Computational and Systems Biology

    A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity

    Adam C Palmer et al.
    Drugs in a curative chemotherapy regimen are independently effective and resisted by different mechanisms, so cancer cells have little chance of surviving all drugs, and this benefit occurs without synergistic interactions.
    1. Cancer Biology

    Breast Cancer: Targeting mutant estrogen receptors

    Suzanne E Wardell et al.
    A drug used in hormone replacement therapy can target estrogen receptors that have become resistant to breast cancer treatments.
    Insight
    Available as:
    • HTML
    • PDF
    1. Cell Biology
    2. Computational and Systems Biology

    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

    Anil Korkut et al.
    Data-driven systems biology models of signaling predict cellular response to untested perturbations and can nominate drug combinations to overcome drug resistance in cancer cells.
    1. Human Biology and Medicine

    Cancer: Designer antiandrogens join the race against drug resistance

    Jatinder S Josan, John A Katzenellenbogen
    Insight
    Available as:
    • HTML
    • PDF
    1. Cancer Biology

    KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

    Elsa B Krall et al.
    Loss of KEAP1 modulates sensitivity to targeted therapies in lung cancer.
    1. Human Biology and Medicine

    Overcoming mutation-based resistance to antiandrogens with rational drug design

    Minna D Balbas et al.
    Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.
    1. Cancer Biology

    The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

    Sean W Fanning et al.
    Bazedoxifene's SERD activities enable it to resist the impact of activating ESR1 mutations in breast cancer.
    1. Structural Biology and Molecular Biophysics
    2. Human Biology and Medicine

    Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

    Sean W Fanning et al.
    Two common mutant versions of estrogen receptor alpha achieve constitutive activity and hormone-resistance by preferentially adopting a suite of conformations that expose the coregulator-binding surface.
    1. Cancer Biology
    2. Cell Biology

    Genetic Diversity: Driving cancer evolution

    Devon M Fitzgerald, Susan M Rosenberg
    Tumor-growth-factor-beta signaling helps cancer cells to evolve and become resistant to drugs by down-regulating accurate DNA repair.
    Insight
    Available as:
    • HTML
    • PDF

Refine your results by:

Type
Research categories